Pharmacoeconomic evaluation of first-line tislelizumab for extensive-stage small cell lung cancer using a comparative validation of traditional survival and machine learning models. - Li Y; Zou Y; Liang C; Feng Z; Lu S; Wang G; Meng G (Frontiers in public health, 2026)